Damora Therapeutics (DMRA) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $40.00 from $35.00 | Jul 30, 2026 |
| Jefferies | Initiated Coverage | Buy | $50.00 | Jul 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Jul 21, 2026 |
| Wedbush | Maintained | Outperform | $35.00 | Jun 12, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $45.00 | Jun 11, 2026 |
| Wedbush | Initiated Coverage | Outperform | $35.00 | May 28, 2026 |
| RBC Capital | Initiated Coverage | Outperform | $40.00 | Apr 24, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $46.00 | Mar 25, 2026 |
| Guggenheim | Maintained | Buy | $40.00 from $36.00 | Feb 17, 2026 |
| UBS | Initiated Coverage | Buy | $45.00 | Feb 17, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $46.00 | Jan 7, 2026 |
| Guggenheim | Maintained | Buy | $36.00 from $32.00 | Dec 8, 2025 |
| Guggenheim | Initiated Coverage | Buy | $32.00 | Dec 1, 2025 |
| Oppenheimer | Maintained | Outperform | $10.00 from $9.00 | Oct 17, 2024 |
| Oppenheimer | Maintained | Outperform | $9.00 from $10.00 | Jun 10, 2024 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Sep 28, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $2.00 from $12.00 | Aug 21, 2023 |
| SVB Leerink | Downgraded | Outperform → Market Perform | $2.00 from $13.00 | Aug 15, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 | Aug 1, 2023 |
| Oppenheimer | Maintained | Outperform | $12.00 | Aug 1, 2023 |
Frequently asked questions
What is the price target for DMRA stock?
The average 12-month analyst price target for Damora Therapeutics (DMRA) is $45.00, with a high estimate of $50.00 and a low of $40.00, across 3 analysts.
Is DMRA a buy, sell, or hold?
Analysts covering Damora Therapeutics currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for DMRA?
The average price target of $45.00 implies 62.07% upside from the last price of $27.77.
What is the latest analyst rating on DMRA?
On Jul 30, 2026, Wedbush maintained Damora Therapeutics at Outperform with a price target of $40.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.